Exscientia (EXAI) Revenue & Revenue Breakdown
Exscientia Revenue Highlights
Latest Revenue (Y)
$24.96M
Latest Revenue (Q)
$5.29M
Main Segment (Y)
Licensing Fees - Upfront Payments and Research Funding
Main Geography (Y)
UNITED STATES
Exscientia Revenue by Period
Exscientia Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $24.96M | -24.14% |
| 2022-12-31 | $32.90M | 20.01% |
| 2021-12-31 | $27.41M | 107.98% |
| 2020-12-31 | $13.18M | 10.39% |
| 2019-12-31 | $11.94M | - |
Exscientia generated $24.96M in revenue during NA 2023, up -24.14% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Exscientia Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $5.29M | 117.70% |
| 2023-12-31 | $2.43M | -72.64% |
| 2023-09-30 | $8.88M | 195.48% |
| 2023-06-30 | $3.01M | -47.82% |
| 2023-03-31 | $5.76M | -29.74% |
| 2022-12-31 | $8.20M | 16.59% |
| 2022-09-30 | $7.03M | -18.75% |
| 2022-06-30 | $8.66M | -5.52% |
| 2022-03-31 | $9.16M | 120.82% |
| 2021-12-31 | $4.15M | -82.49% |
| 2021-09-30 | $23.69M | 5762.11% |
| 2021-06-30 | $404.13K | -94.43% |
| 2021-03-31 | $7.26M | 24.73% |
| 2020-12-31 | $5.82M | 367.54% |
| 2020-09-30 | $1.25M | -48.50% |
| 2020-06-30 | $2.42M | - |
| 2020-03-31 | $2.42M | 6.20% |
| 2019-12-31 | $2.28M | - |
| 2019-09-30 | $2.28M | - |
| 2019-06-30 | $2.28M | - |
| 2019-03-31 | $2.28M | - |
Exscientia generated $5.29M in revenue during Q1 2024, up 117.70% compared to the previous quarter, and up 64.51% compared to the same period a year ago.
Exscientia Revenue Breakdown
Exscientia Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Licensing Fees - Opt-in Payments and Milestones Achieved | - | - | $18.58M |
| Service Fees | $104.00K | - | - |
| Licensing Fees - Upfront Payments and Research Funding | $19.98M | $26.55M | $8.32M |
| Service fees | - | $670.00K | $452.00K |
Exscientia's latest annual revenue breakdown by segment (product or service), as of Dec 23: Licensing Fees - Upfront Payments and Research Funding (99.48%), and Service Fees (0.52%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|
| Licensing Fees - Upfront Payments and Research Funding | $16.97M | $3.01M | $6.81M | $5.96M | $6.80M |
| Service Fees | - | - | - | - | - |
| Service fees | - | - | - | $334.00K | $336.00K |
| Licensing Fees - Opt-in Payments and Milestones Achieved | - | - | - | - | - |
Exscientia's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Licensing Fees - Upfront Payments and Research Funding (100.00%).
Exscientia Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| UNITED STATES | $14.38M | $21.00M | $22.20M |
| FRANCE | $5.08M | - | - |
| Other Countries Not Individually Disclosed | - | - | $3.56M |
| Rest of Europe | $619.00K | $6.22M | - |
Exscientia's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (71.64%), FRANCE (25.28%), and Rest of Europe (3.08%).
Exscientia Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| RXRX | Recursion Pharmaceuticals | $44.58M | $13.79M |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| EXAI | Exscientia | $24.96M | $5.29M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| PDSB | PDS Bio | - | - |
| ZURA | Zura Bio | - | - |
| LPTX | Leap Therapeutics | - | - |
| ELEV | Elevation Oncology | - | - |
| UBX | Unity Bio | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| AVIR | Atea Pharmaceuticals | - | - |
EXAI Revenue FAQ
What is Exscientia’s yearly revenue?
Exscientia's yearly revenue for 2023 was $24.96M, representing a decrease of -24.14% compared to 2022. The company's yearly revenue for 2022 was $32.9M, representing an increase of 20.01% compared to 2021. EXAI's yearly revenue for 2021 was $27.41M, representing an increase of 107.98% compared to 2020.
What is Exscientia’s quarterly revenue?
Exscientia's quarterly revenue for Q1 2024 was $5.29M, a 117.70% increase from the previous quarter (Q4 2023), and a -8.18% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.43M, a -72.64% decrease from the previous quarter (Q3 2023), and a -70.37% decrease year-over-year (Q4 2022). EXAI's quarterly revenue for Q3 2023 was $8.88M, a 195.48% increase from the previous quarter (Q2 2023), and a 26.29% increase year-over-year (Q3 2022).
What is Exscientia’s revenue growth rate?
Exscientia's revenue growth rate for the last 3 years (2021-2023) was -8.96%, and for the last 5 years (2019-2023) was 109.03%.
What are Exscientia’s revenue streams?
Exscientia's revenue streams in c 23 are Service Fees, and Licensing Fees - Upfront Payments and Research Funding. Service Fees generated $104K in revenue, accounting 0.52% of the company's total revenue Licensing Fees - Upfront Payments and Research Funding generated $19.98M in revenue, accounting 99.48% of the company's total revenue, down -24.77% year-over-year.
What is Exscientia’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Exscientia was Licensing Fees - Upfront Payments and Research Funding. This segment made a revenue of $19.98M, representing 99.48% of the company's total revenue.